In the previous articles of this series, part 1, part 2, part 3, and part 4, I have discussed in detail about the pros and cons of Celgene's (NASDAQ:CELG) key drugs such as Revlimid, Pomalyst, and Abraxane. The company announced its full-year 2016 results on January 26, 2017.
Not much seems to have changed for Celgene's core oncology business. Growth drivers for Revlimid and Pomalyst continue to be the same as those discussed in the previous articles.
To reduce its over-dependence on oncology revenues, CELG has diversified into immunology and inflammation (I&I) segment. And this strategy seems to have worked really well.
